Nuclear PRMT5 is a biomarker of sensitivity to tamoxifen in ERα+ breast cancer

Nuclear PRMT5 is a biomarker of sensitivity to tamoxifen in ERα⁺ breast cancer

Coralie Poulard, Thuy Ha Pham, Youenn Drouet, Julien Jacquemetton, Ausra Surmielova, Loay Kassem, Benoite Mery, Christine Lasset, Jonathan Reboulet, Isabelle Treilleux, Elisabetta Marangoni, Olivier Trédan, Muriel Le Romancer

EMBO Molecular Medicine

https://doi.org/10.15252/emmm.202217248